The primary legal issue is whether Novo Nordisk knew or should have known about the heightened risks for gastroparesis/stomach paralysis that these drugs posed to users and failed to warn doctors and patients of this risk
Modern medical science recognizes it as a chronic disease influenced by genetics, environment, and hormones
This new drug, semaglutide, was first approved for diabetes in 2017 under the brand name Ozempic and then in 2021 for weight loss as Wegovy
The United States: The Undisputed GLP-1 Leader No country comes close to the United States in volume or intensity of GLP-1 uptake
Consult your doctor before use if you have: Pregnancy or breastfeeding Active cancer or history of hormone-sensitive malignancy Pituitary disorders Uncontrolled diabetes or severe metabolic disease Known hypersensitivity to peptide products Drug interactions There are no well-defined drug interaction studies for CJC-1295
Nutritional optimization, slower weight loss pacing, and supplementation of documented deficiencies are generally more effective approaches than discontinuation
)
